Halozyme Therapeutics (HALO) Net Margin (2010 - 2026)
Halozyme Therapeutics (HALO) reported Net Margin of 39.83% for Q1 2026, down 476.0% year-over-year from 10.59% in Q1 2025, and up 227.09% quarter-over-quarter from 31.34% in Q4 2025.
Halozyme Therapeutics (HALO) Net Margin (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 17 years of Net Margin data on file, last reported at 39.83% in Q1 2026.
- Net Margin for Q1 2026 came in at 39.83%, down 476.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 23.13% (down 2164.0% YoY), and the FY2025 annual result was 22.69%, down 2105.0% from the prior year.
- Net Margin improved to 39.83% in Q1 2026 per HALO's latest filing, from 31.34% in the prior quarter.
- Over five years, Net Margin peaked at 51.25% in Q1 2022 and troughed at 31.34% in Q4 2025.
- A 5-year average of 34.51% and a median of 39.22% in 2024 frame the typical range for Net Margin.
- On a YoY basis, Net Margin climbed as much as 1992 bps in 2022 and fell as far as 15749 bps in 2022.
- A 5-year view of Net Margin shows it stood at 31.79% in 2022, then increased by 17 bps to 37.12% in 2023, then grew by 24 bps to 45.98% in 2024, then sank by 168 bps to 31.34% in 2025, then surged by 227 bps to 39.83% in 2026.
- Business Quant data shows HALO's Net Margin at 39.83% in Q1 2026, 31.34% in Q4 2025, and 49.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 39.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 39.83% |
| Dec 31, 2025 | -31.34% |
| Sep 30, 2025 | 49.47% |
| Jun 30, 2025 | 50.70% |
| Mar 31, 2025 | 44.59% |
| Dec 31, 2024 | 45.98% |
| Sep 30, 2024 | 47.23% |
| Jun 30, 2024 | 40.30% |
| Mar 31, 2024 | 39.22% |
| Dec 31, 2023 | 37.12% |
| Sep 30, 2023 | 37.88% |
| Jun 30, 2023 | 33.82% |
| Mar 31, 2023 | 24.43% |
| Dec 31, 2022 | 31.79% |
| Sep 30, 2022 | 29.49% |
| Jun 30, 2022 | 14.89% |
| Mar 31, 2022 | 51.25% |
| Dec 31, 2021 | 65.46% |
| Sep 30, 2021 | 186.99% |
| Jun 30, 2021 | 67.02% |